Home › Chronic Lymphocytic Leukemia › Delaware › Newark
Chronic Lymphocytic Leukemia clinical trials in Newark, DE
4 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
- Christiana Care, Newark
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Christiana Care Hospital - Helen F Graham Cancer Center, Newark
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
- Cincinnati, OH14 studies
Other studies in Newark
- Non-Small Cell Lung Cancer16 studies
- Prostate Cancer10 studies
- Colorectal Cancer9 studies
- Lung Cancer9 studies
- Breast Cancer8 studies
- Metastatic Cancer7 studies
- Cancer (all types)6 studies
- Pancreatic Cancer6 studies
- Ovarian Cancer5 studies
- Follicular Lymphoma4 studies
- Stomach Cancer4 studies
- Melanoma4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.